Clinical risk factors for cytomegalovirus retinitis in patients with AIDS

Ophthalmology

Volumn 111, Issue 7, 2004, Pages 1326-1333

  Hodge, William G ^a,b   Boivin, Jean François ^b   Shapiro, Stanley H ^b   Lalonde, Richard G ^c   Shah, Kirtida C ^a   Murphy, Bradley D ^a   Dionne, Michel A ^a   Goela, Aashish ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAMNESIS; ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; HOMOSEXUALITY; HOSPITAL CARE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYCOBACTERIOSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETINITIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CYTOMEGALOVIRUS RETINITIS; HUMANS; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 3042561518     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2004.03.001     Document Type: Article

References (34)

1. Holland G.N., Pepose J.S., Simons K.B., et al. Ocular disease in the acquired immune deficiency syndrome clinicopathological correlations. Secchi A.G., Fregona I.A. Modern Trends in Immunology and Immunopathology of the Eye. 1989;132-155 Saunders, Milan
2. Montaner J.S., Le T., Hogg R., et al. The changing spectrum of AIDS index diseases in Canada. AIDS. 8:1994;693-696
3. Munoz A., Schrager L.K., Bacellar H., et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study 1985-1991. Am J Epidemiol. 137:1993;423-438
4. Holland G., Tufail A., Jordan M.C. Cytomegalovirus diseases. Pepose J.S., Holland G.N., Wilhelmus K.R. Ocular Infection & Immunity. 1996;1088-1129 Mosby, New York
5. Pertel P., Hirschtick R., Phair J., et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 5:1992;1069-1074
6. McDonald C.K., Kuritzkes D.R. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med. 157:1997;951-959
7. Casado J.L., Arrizabalaga J., Montes M., et al. Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group. AIDS. 13:1999;1497-1502
8. Doan S., Cochereau I., Guvenisik N., et al. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Am J Ophthalmol. 128:1999;250-251
9. Lewis J.S., Terriff C.M., Coulston D.R., et al. Protease inhibitors a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther. 19:1997;187-214
10. Le Moing V., Chene G., Carrieri M.P., et al. Predictors of virologic rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 16:2002;21-29
11. The Roche Cooperative Oral Ganciclovir Study Group, Spector S.A., McKinley G.F., Lalezari J.P., et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 334:1996;1491-1497
12. Anderson R.D., Griffy K.G., Jung D., et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus-seropositive patients. Clin Ther. 17:1995;425-432
13. Masur H., Whitcup S.M., Cartwright C., et al. Advances in the management of AIDS-related cytomegalovirus retinitis. Ann Intern Med. 125:1996;126-136
14. Kuppermann B.D., Petty J.G., Richman D.D., et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 115:1993;575-582
15. Drew W.L., Mintz L., Miner R.C., et al. Prevalence of cytomegalovirus infection in homosexual men. J Infect Dis. 143:1981;188-192
16. Gallant J.E., Moore R.D., Richman D.D., et al. The Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis. 166:1992;1223-1227
17. Groupe d'Épidémiologie Clinique du SIDA en Aquitaine, Saillour F., Bernard N., Dequae-Merchadou L., et al. Predictive factors of occurrence of cytomegalovirus disease and impact on survival in the Aquitaine Cohort in France, 1985 to 1994. J Acquir Immune Defic Syndr Hum Retrovirol. 17:1998;171-178
18. Holland G.N., Pepose J.S., Pettit T.H., et al. Acquired immune deficiency syndrome. Ocular manifestations. Ophthalmology. 90:1983;859-873
19. Schiffer V., Mentha G., Giostra E., et al. Cytomegalovirus in liver transplantation incidence and groups at risk. [in French] Schweiz Med Wochenschr. 124:1994;631-636
20. Burke M., Yust I., Katlama C., et al. AIDS in Europe Study Group. Cytomegalovirus retinitis in patients with AIDS in Europe. Eur J Clin Microbiol Infect Dis. 16:1997;876-882
21. Holland G.N., Buhles W.C., Mastre B., Kaplan H.J. A controlled retrospective study on ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. Arch Ophthalmol. 107:1989;1759-1766
22. Gendelman H.E., Phelps W., Feigenbaum L., et al. Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci U S A. 83:1986;9759-9763
23. Fay M.T., Freeman W.R., Wiley C.A., et al. Atypical retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 105:1988;483-490
24. Cozzi-Lepri A., Phillips A.N., Miller V., et al. Changes in viral load in people with virologic failure who remain on the same HAART regimen. Antiv Ther. 8:2003;127-136
25. Finzi D., Blankson J., Siliciano J.D., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 5:1999;512-517
26. Rachlis A.R., Zarowny D.P. Guidelines for antiretroviral therapy for HIV infection. CMAJ. 158:1998;496-505
27. Binquet C., Saillour F., Bernard N., et al. Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease Aquitaine Cohort, 1986-1997. Eur J Epidemiol. 16:2000;425-432
28. Burke M., Yust I., Katlama C., et al. AIDS in Europe Study Group. Cytomegalovirus retinitis in patients with AIDS in Europe. Eur J Clin Microbiol Infect Dis. 16:1997;876-882
29. Tufail A., Holland G.N., Fisher T.C., et al. Increased polymorphonuclear leucocyte rigidity in HIV infected individuals. Br J Ophthalmol. 84:2000;727-731
30. Glasgow B.J. Evidence for breaches of the retinal vasculature in acquired immune deficiency syndrome angiopathy. A fluorescent microsphere study. Ophthalmology. 104:1997;753-760
31. Glasgow B.J., Weisberger A.K. A quantitative and cartographic study of retinal microvasculopathy in acquired immunodeficiency syndrome. Am J Ophthalmol. 118:1994;46-56
32. Rao N.A., Zhang J., Ishimoto S. Role of retinal vascular endothelial cells in development of CMV retinitis. Trans Am Ophthalmol Soc. 96:1998;111-123
33. Scholz M., Blaheta R.A., Vogel J., et al. Cytomegalovirus-induced transendothelial cell migration a closer look at intercellular communication mechanisms. Intervirology. 42:1999;350-356
34. Jabs D.A. Ocular Manifestations of HIV infection. Trans Am Ophthalmol Soc. 93:1995;623-683